What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology.
about
Kruppel-like factor 15 is critical for vascular inflammationUnresolved questions in rheumatology: motion for debate: the data support evidence-based management recommendations for cardiovascular disease in rheumatoid arthritisProtein glutathionylation in cardiovascular diseasesTargeting Low Disease Activity in Elderly-Onset Rheumatoid Arthritis: Current and Future Roles of Biological Disease-Modifying Antirheumatic DrugsMyD88-dependent interplay between myeloid and endothelial cells in the initiation and progression of obesity-associated inflammatory diseases.Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers.Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis.Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies.Tumor Necrosis Factor-α Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis.Oxidized LDL: diversity, patterns of recognition, and pathophysiology.Cardiovascular risk management in patients with inflammatory arthritis: what is good for the joint is good for the heart and vice versa!Cardiovascular disease and rheumatoid arthritis: an update.Hepatic steatosis, carotid plaques and achieving MDA in psoriatic arthritis patients starting TNF-α blockers treatment: a prospective study.Cardiovascular co-morbidity in rheumatic diseases.Psoriasis and new-onset diabetes: a Danish nationwide cohort studyHypertension in rheumatoid arthritis.Infliximab improves vascular stiffness in patients with rheumatoid arthritis.Molecular mechanisms and clinical implications of reversible protein S-glutathionylation.Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis.Evidence that cytokines play a role in rheumatoid arthritis.New and emerging therapies for the treatment of rheumatoid arthritis.Microvesicles Derived from Inflammation-Challenged Endothelial Cells Modulate Vascular Smooth Muscle Cell Functions.Vascular function and inflammation in rheumatoid arthritis: the role of physical activity.Cardiovascular safety of biologic therapies for the treatment of RA.Lipid profile changes in patients with rheumatic diseases receiving a treatment with TNF-α blockers: a meta-analysis of prospective studies.Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis?Cardiovascular risk and the use of biologic agents in rheumatoid arthritis.Effects of TNFα inhibitors on adiposity and other cardiovascular risk factors: implications for the cardiovascular prognosis in patients with rheumatoid arthritis.Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.The effect of tumour necrosis factor inhibitor therapy on the incidence of myocardial infarction in patients with psoriasis: A retrospective study.Impact of 24 months of anti-TNF therapy versus methotrexate on body weight in patients with rheumatoid arthritis: a prospective observational study.Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis.Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study.Cardiovascular risk factors in high-need psoriasis patients and its implications for biological therapies.The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study.Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis.[Managing comorbidities of inflammatory rheumatic diseases].Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study.
P2860
Q24321728-82EF4E7E-4C65-4AE2-8118-A07A0A426904Q26822912-3305DAFA-9F03-4A1D-80B6-C2F0A32328FEQ27009841-BC052690-A5B8-4F1D-BD9F-D364C5D43277Q28073436-835C4280-4165-4D9F-993B-9E566441B2A1Q33569870-F6283CBC-6D2C-4459-99C5-8157E3B88C81Q33659058-1F6B4500-8D4B-41BD-9AA0-65AF33359A2AQ33686973-2F3C17C4-A437-4FA4-9CB9-4CFA75729215Q33823950-CF6C31DC-2F94-4DF2-A191-C465F715E90AQ33871929-A35D3FE3-5AED-4352-9066-A7B7AB93FA9BQ33879138-348C73B3-EE21-4B50-B839-5D4C657101B2Q34167653-740330F5-98F9-46E4-B8BD-88562D86913AQ36218375-C720DBD8-90D9-400E-A4C1-83419A2EA8CBQ36633179-EC780007-EAAC-4348-8B29-1ED150919D14Q36835851-1C36554A-69A7-46CF-8CBC-CD27EF031C95Q37022693-A91B31F4-8CE4-44DD-9704-7DBCC67094D5Q37158219-A4ECEE46-A8A8-4B82-AAC1-3CB948918246Q37245192-8AAD68CE-FE9F-42CC-AEF7-43A900EC4145Q37262124-C0063D75-559D-4CD0-9155-6A60713AE0C2Q37300823-7189AED2-96CB-4863-9843-416731CA0850Q37316594-49818024-4E97-4AE9-9963-00303194724EQ37358229-27997165-D82D-4467-88D5-801E1D99900EQ37580782-87E6A3B5-C49A-470A-8285-5CD7DF5ED0D2Q37723293-1F346666-C371-4C95-8666-3806DF0E16D6Q37956137-3FA17F2A-50A3-4BBB-BE4C-205374005592Q38181566-818828CB-C85B-4DA4-859C-AB7E1EEB14FFQ38185646-D5C03978-FC4D-45E9-BAC8-72372502F01FQ38260198-E44E10B2-CE20-46C3-96AB-D576D977991CQ38323310-73E732E1-A05C-419E-9902-D06229F397E4Q38993250-354ECE04-F2A4-4CA8-9CAC-73368EDBE938Q39158398-DBBD2EDC-5FC0-4228-BF5B-9A2A00C78ACAQ39861020-EBB321DE-AC3E-446B-B794-6FC1BD6F121AQ40386790-6C00A7BC-D583-4558-9AFF-432F3B1C78AFQ42696887-4689C69D-E2E7-40FA-B05F-9B5304CABE7DQ43477625-C74975A7-1EA5-47C1-B9D4-87646E617193Q43760972-F71E6CCF-317A-4BF7-AB91-E68C1DFD79E0Q44293608-FCFA3178-3456-4537-8752-2A77D748C130Q44393048-D07FD8D4-EB1F-4035-B72B-4B86B60EC275Q44398860-64837334-B264-4E1C-88AC-9E8BEEC00716
P2860
What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
What effects might anti-TNFalp ...... ardiovascular pathophysiology.
@ast
What effects might anti-TNFalp ...... ardiovascular pathophysiology.
@en
type
label
What effects might anti-TNFalp ...... ardiovascular pathophysiology.
@ast
What effects might anti-TNFalp ...... ardiovascular pathophysiology.
@en
prefLabel
What effects might anti-TNFalp ...... ardiovascular pathophysiology.
@ast
What effects might anti-TNFalp ...... ardiovascular pathophysiology.
@en
P2860
P356
P1476
What effects might anti-TNFalp ...... cardiovascular pathophysiology
@en
P2093
D P M Symmons
P2860
P304
P356
10.1136/ARD.2006.063867
P407
P577
2007-01-24T00:00:00Z